Breaking News Instant updates and real-time market news.

ARQL

ArQule

$6.29

0.04 (0.64%)

, BXG

Bluegreen Vacations

$8.01

0.01 (0.13%)

08:57
06/14/19
06/14
08:57
06/14/19
08:57

Fly Intel: Pre-market Movers

HIGHER: ArQule (ARQL), up 46% after announcing preliminary results from the company's phase 1 dose escalation study for ARQ 531... Bluegreen Vacations (BXG), up 28% after announcing that Bass Pro and its affiliates and the company have settled their prior disputes and have amended their marketing and promotions agreement to reinstate Bluegreen's access to Bass Pro's marketing channels... Karyopharm (KPTI), up 2% after announcing three presentations highlighting new and updated data from the Phase 1b/2 STOMP study evaluating selinexor... Kura Oncology (KURA), up 11% after announcing updated interim data from the ongoing Phase 2 clinical trial of its lead drug candidate, tipifarnib, in patients with relapsed or refractory peripheral T-cell lymphoma... Red Robin (RRGB), up 2%, extending yesterday's gains after announcing it would consider a "bona fide" takeover offer made by Vintage Capital. DOWN AFTER EARNINGS: Broadcom (AVGO), down 9%. LOWER: Seres Therpeutics (MCRB), down 23% after its 26.667M share secondary offering priced at $2.25 per share... Global Blood Therapeutics (GBT), down 5% after reporting results from its HOPE study... WhiteHorse Finance (WHF), down 5% after filing to sell an undisclosed amount of common stock for holders.

ARQL

ArQule

$6.29

0.04 (0.64%)

BXG

Bluegreen Vacations

$8.01

0.01 (0.13%)

KPTI

Karyopharm

$5.75

0.33 (6.09%)

KURA

Kura Oncology

$18.49

0.97 (5.54%)

RRGB

Red Robin

$33.46

8.01 (31.47%)

AVGO

Broadcom

$281.95

1.84 (0.66%)

NETS

Netshoes

$3.80

0.39 (11.44%)

MCRB

Seres Therapeutics

$2.82

-0.47 (-14.29%)

GBT

Global Blood Therapeutics

$57.45

2.58 (4.70%)

WHF

WhiteHorse Finance

$14.50

(0.00%)

  • 14

    Jun

  • 14

    Jun

  • 14

    Jun

  • 14

    Jun

  • 18

    Jun

  • 19

    Jun

  • 25

    Jun

  • 06

    Jul

  • 09

    Jul

  • 14

    Jun

  • 14

    Jun

ARQL ArQule
$6.29

0.04 (0.64%)

01/07/19
PIPR
01/07/19
NO CHANGE
Target $235
PIPR
Overweight
Piper Jaffray views price paid for Loxo by Eli Lilly as fair
Piper Jaffray analyst Tyler Van Buren views the price of $235 per share paid by Eli Lilly (LLY) for Loxo Oncology (LOXO) as fair. The analyst says the price is near the $250-plus he previously thought was achievable in an acquisition scenario for Loxo. Other names in the precision medicine/oncology space that could be up today as a result of the buyout are Agios Pharmaceuticals (AGIO), ArQule (ARQL), Array BioPharma (ARRY), Blueprint Medicines (BPMC), Kura Oncology (KURA), Mirati Therapeutics (MRTX) and others, Van Buren tells investors in a research note. He raised his price target for Loxo Oncology to $235 from $200 and keeps an Overweight rating on the shares.
04/11/19
RBCM
04/11/19
INITIATION
Target $9
RBCM
Outperform
ArQule initiated with an Outperform at RBC Capital
RBC Capital analyst Gregory Renza initiated ArQule with an Outperform rating and a price target of $9. The analyst is positive on the company's "unique clinical portfolio of precision-based kinase inhibitors in oncology and orphan disease." Renza also expects that portfolio to appreciate over the year with additional clinical data for ARQ '531 inhibitor and progress on miransertib further de-risking the investment story.
01/16/19
EAMC
01/16/19
INITIATION
Target $7
EAMC
Buy
ArQule initiated with a Buy at Empire
Empire initiated ArQule with a Buy and $7 price target.
05/29/19
RILY
05/29/19
NO CHANGE
Target $11
RILY
Buy
ArQule price target raised to $11 from $6.75 at B. Riley FBR
B. Riley FBR analyst George Zavoico raised his price target for ArQule to $11 from $6.75 ahead of what he expects will be "positive" Phase I safety and efficacy results for ARQ531 at the European Hematology Association conference in June. The analyst reiterates a Buy rating on the shares.
BXG Bluegreen Vacations
$8.01

0.01 (0.13%)

08/17/18
BOFA
08/17/18
DOWNGRADE
Target $19
BOFA
Underperform
Bluegreen Vacations downgraded to Underperform from Buy at BofA/Merrill
BofA/Merrill analyst Shaun Kelley downgraded Bluegreen Vacations two notches to Underperform from Buy and lowered its price target to $19 from $26 following the Q2 miss. Kelley lowered estimates to reflect slower sales growth and believes a valuation closer to peers is warranted given execution risks, reduced visibility on VOI sales, and lack of catalysts.
03/20/19
FBCO
03/20/19
INITIATION
Target $16
FBCO
Neutral
Bluegreen Vacations assumed with a Neutral at Credit Suisse
Credit Suisse analyst Ben Combes assumed coverage of Bluegreen Vacations with a Neutral rating and $16 price target.
06/14/19
STFL
06/14/19
UPGRADE
Target $10
STFL
Buy
Bluegreen Vacations upgraded to Buy from Hold at Stifel
Stifel analyst Simon Yarmak upgraded Bluegreen Vacations (BXG) to Buy from Hold and raised his price target for the shares to $10 from $8. Since BBX Capital (BBX) terminated its merger with Bluegreen on May 22, shares of the latter have traded off over 46%, Yarmak tells investors in a research note. Additionally, the following week, the termination with Bass Pro further pressured the stock lower, the analyst adds. However, he believes Bluegreen Vacations shares are now oversold and should bounce from here after the company reached an agreement with Bass Pro.
03/05/19
STFL
03/05/19
DOWNGRADE
Target $16
STFL
Hold
Bluegreen Vacations downgraded to Hold from Buy at Stifel
Stifel analyst Simon Yarmak downgraded Bluegreen Vacations (BXG) to Hold from Buy after BBX Capital (BBX) announced that it is once again taking Bluegreen private.
KPTI Karyopharm
$5.75

0.33 (6.09%)

03/15/19
WEDB
03/15/19
NO CHANGE
WEDB
Wedbush views Karyopharm 's PDUFA date extension as a positive
Wedbush analyst David Nierengarten maintained an Outperform rating and $6 price target on Karyopharm. In a note titled "FDA Extends PDUFA by Three Months," he said he is inclined to view the extension as a positive for the company "given the negative sentiment on the name and general belief that an April 6, 2019 approval was unlikely."
03/01/19
JPMS
03/01/19
DOWNGRADE
Target $7
JPMS
Neutral
Karyopharm downgraded to Neutral from Overweight at JPMorgan
JPMorgan analyst Eric Joseph downgraded Karyopharm Therapeutics to Neutral and lowered his price target for the shares to $7 from $21. The analyst sees a "rocky regulatory road" forward for the company.
02/28/19
HCWC
02/28/19
NO CHANGE
Target $30
HCWC
Buy
H.C. Wainwright says selinexor expectations not changed by ODAC recommendation
After the FDA's Oncologic Drugs Advisory Committee, or ODAC, voted on February 26 to recommend that the FDA wait for the Phase 3 BOSTON trial results before deciding on selinexor's NDA application, H.C. Wainwright analyst Edward White noted that the decision was not unanimous and said "the FDA typically but does not always follow the ODAC panel's recommendations." It is possible that a delay to wait for the BOSTON data could push out a selinexor launch by one year or more, but the ODAC recommendation is "not changing our expectations," stated White, who keeps a Buy rating and $30 price target on shares of Karyopharm.
02/27/19
WEDB
02/27/19
NO CHANGE
Target $6
WEDB
Outperform
Karyopharm price target lowered to $6 from $14 at Wedbush
Wedbush analyst David Nierengarten lowered his price target for Karyopharm to $6 from $14 following the outcome of the FDA Advisory Committee Meeting regarding the potential approval of selinexor in penta-refractory multiple myeloma by the PDUFA date of April 6, 2019. The analyst notes that the panel voted 8 yes to 5 no to the question of "Should the approval of selinexor be delayed until results of the randomized phase 3 trial, BOSTON, are available?," as key concerns around safety, dose reductions and study design previously introduced in the published briefing docs prevailed, although the vote also indicated a receptiveness, particularly among treating physicians, for a novel drug like selinexor that could help serve this highly refractory patient population with limited treatment options. Nierengarten reiterates an Outperform rating on the shares.
KURA Kura Oncology
$18.49

0.97 (5.54%)

05/24/19
SBSH
05/24/19
NO CHANGE
Target $25
SBSH
Buy
Kura Oncology price target raised to $25 from $18 at Citi
Citi analyst Joel Beatty raised his price target for Kura Oncology to $25 from $18 saying he believes the data to date support that tipifarnib is likely effective for HRAS-mutant head and neck squamous cell carcinoma. More Phase 2 data in this setting in the second half of 2019 could add further support, Beatty tells investors in a research note. He keeps a Buy rating on Kura Oncology shares.
01/18/19
PIPR
01/18/19
NO CHANGE
Target $25
PIPR
Overweight
Kura Oncology shares remain 'significantly undervalued,' says Piper Jaffray
Kura Oncology today provided evidence that tipifarnib could be active in patients with no abdominal pain and/or nodal/liver met disease, both of which are associated with high CXCL12 expression, Piper Jaffray analyst Tyler Van Buren tells investors in a research note. The analyst estimates tipifarnib's opportunity in the HRAS-driven head and neck squamous cell carcinomas opportunity alone is worth $500M-plus in peak sales. However, with the recent data in CXCL12-driven peripheral T-cell lymphomas presented and now potentially pancreatic cancer, these estimates "could be pushed significantly higher over time," Van Buren adds. He continues to believe Kura Oncology shares are "significantly undervalued" and keeps an Overweight rating on the name with a $25 price target.
04/03/19
PIPR
04/03/19
NO CHANGE
PIPR
Overweight
Piper says Kura's potential patient population for tipifarnib keeps growing
After Kura Oncology presented additional data on tipifarnib, a farnesyltransferase inhibitor/HRAS inhibitor that downregulates expression of CXCL12, Piper Jaffray analyst Tyler Van Buren said the number of potential indications for the drug "continues to multiply" as initial clinical data suggest diffuse large B-cell lymphoma and cutaneous T-cell lymphoma patients could benefit from treatment in addition to the already identified cancer indications. The "broad mechanism of tipifarnib is becoming clear" and the potential patient population keeps growing, "well beyond what investors are currently appreciating," according to Van Buren. He keeps an Overweight rating on Kura shares.
RRGB Red Robin
$33.46

8.01 (31.47%)

04/05/19
MAXM
04/05/19
NO CHANGE
Target $25
MAXM
Hold
Red Robin price target lowered to $25 from $29 at Maxim
Maxim analyst Stephen Anderson lowered his price target on Red Robin to $25 and kept his Hold rating after its CEO transition announcement and a bigger than expected Q1 comps decline outlook. The analyst believes that the CEO exit reduces the visibility for the company's turnaround, also lowering his Q1 EPS forecast to 42c from 56c and FY19 view to $1.23 from $1.42 on the disappointing comps guidance.
06/14/19
MAXM
06/14/19
UPGRADE
Target $49
MAXM
Buy
Red Robin upgraded to Buy from Hold at Maxim
Maxim analyst Stephen Anderson upgraded Red Robin to Buy from Hold and raised his price target on the shares to $49, citing his view that a takeover is increasingly likely following the letter sent to the board by investor Vintage Capital.
06/13/19
SPHN
06/13/19
NO CHANGE
Target $36
SPHN
Overweight
Red Robin 'interesting' for prospective private equity buyers, says Stephens
Stephens analyst Will Slabaugh notes that Vintage Capital filed a 13-D stating its belief that the Board of Red Robin should "immediately commence a comprehensive review of strategic alternatives, including an auction of the Issuer", with Vintage prepared to call a special meeting of shareholders to potentially remove members of the Board if they do not promptly commit to reviewing possible strategic-alternatives. While Red Robin has shown "poor business momentum" recently, the analyst points out that the company's substantial cash-flow profile, refranchising potential, and attractive valuation make the company "interesting" for prospective Private Equity buyers. Vintage Capital now holds an 11.6% stake and stated they "are prepared to bid $40 per-share in the auction process to acquire 100% of the company in an all-cash transaction," Slabaugh adds. The analyst has an Overweight rating and $36 price target on the shares.
05/16/19
MAXM
05/16/19
NO CHANGE
Target $32
MAXM
Hold
Red Robin price target raised to $32 from $25 at Maxim
Maxim analyst Stephen Anderson raised his price target on Red Robin to $32 ahead of its Q1 results on May 30th. The analyst says his new price target accounts for the possibility of an activist-driven takeover after last week's announcement by Vintage Capital Management taking an 8.5% stake in the company. Anderson also keeps his Hold rating on Red Robin shares.
AVGO Broadcom
$281.95

1.84 (0.66%)

06/14/19
CHLM
06/14/19
NO CHANGE
Target $315
CHLM
Buy
Broadcom price target lowered to $315 from $325 at Craig-Hallum
Craig-Hallum analyst Anthony Stoss reiterated a Buy rating on Broadcom (AVGO) but lowered his price target to $315 after the company reported revenues below the Street and his estimate due to the impact of the Huawei ban as well as Apple (AAPL) weakness. Stoss tells investors in a research note that he still expects Broadcom to benefit from content growth at Apple this year due to the socket win back from Qorvo (QRVO) and new content associated with Wi-Fi 6 and says he continues to like Broadcom's position at Apple longer term and notes its recently signed two-year supply agreement positions the company well for 5G inclusion in iPhones likely coming next year.
06/14/19
JEFF
06/14/19
NO CHANGE
Target $324
JEFF
Buy
Broadcom price target lowered to $324 from $370 at Jefferies
Jefferies analyst Mark Lipacis lowered his price target for Broadcom to $324 from $370 after the company reduced its revenue outlook but he keeps a Buy rating on the shares. The analyst expects an inventory restock in the second half of 2019 and view Broadcom's risk/reward as attractive.
06/14/19
DADA
06/14/19
NO CHANGE
Target $300
DADA
Buy
Broadcom price target lowered to $300 from $325 at DA Davidson
DA Davidson analyst Thomas Diffely lowered his price target on Broadcom to $300 after the company reported a "light" quarter and cut its outlook for the year because of a sharper than anticipated slowdown in Wireless, softness in Storage, and the loss of revenue associated with the Huawei export restrictions. The analyst says he is also adopting a "more conservative" near-term stance, taking Huawei completely out of his model and cutting his FY20 EPS estimates to $24 from $26 per shares to reflect the continued China trade war and inventory digestion by key OEM customers. Longer term however, Diffely keeps his Buy rating on Broadcom given the company's "product diversity, operational track record, cash generation, and best in class margins."
06/14/19
MSCO
06/14/19
NO CHANGE
Target $250
MSCO
Equal Weight
Broadcom price target lowered to $250 from $262 at Morgan Stanley
Morgan Stanley analyst Craig Hettenbach lowered his estimates ahead of Broadcom's earnings report but he is making additional cuts following the report and the company's 8% lowering of its FY19 revenue guidance due to weaker demand. Huawei is roughly a 4% customer, so the negative outlook is "above and beyond" the impact from just that company, said Hettenbach, whose negative near-term view on the business is balanced by the company's "industry leading margins." He keeps an Equal Weight rating on Broadcom, which is down 9.5% in pre-market trading to $255 per share.
NETS Netshoes
$3.80

0.39 (11.44%)

MCRB Seres Therapeutics
$2.82

-0.47 (-14.29%)

04/30/19
JEFF
04/30/19
INITIATION
Target $7
JEFF
Hold
Seres Therapeutics initiated with a Hold at Jefferies
Jefferies analyst Chris Howerton started Seres Therapeutics with a Hold rating and $7 price target. The analyst believes the company's "Ecobiotics" strategy requires additional work with respect to mechanistic understanding and chemistry, manufacturing and controls.
08/03/18
08/03/18
DOWNGRADE
Target $6

Underperform
Seres Therapeutics downgraded to Underperform at BofA/Merrill
As previously reported, BofA/Merrill downgraded Seres Therapeutics to Underperform from Neutral and cut its price target to $6 from $13. Analyst Tazeen Ahmad said management has not provided a timeline yet for the ECOSPOR III study of '109 and pushed out his expected launch date to 2021 from 2020. Ahmad believes Seres' microbiome-based pipeline could yield new treatment options for many diseases but notes the landscape is becoming increasingly competitive.
02/22/19
HCWC
02/22/19
INITIATION
Target $16
HCWC
Buy
Seres Therapeutics assumed with a Buy at H.C. Wainwright
H.C. Wainwright analyst Vernon Bernardino assumed coverage of Seres Therapeutics with a Buy rating and $16 price target. The company is "strongly positioned" in the race to apply a microbiome approach in immune-oncology, Bernardino tells investors in a research note. The company possesses a "differentiated, and in our view, potentially disruptive technology that we expect could generate long-term pipeline value," says the analyst.
10/22/18
CHDN
10/22/18
INITIATION
Target $15
CHDN
Buy
Seres Therapeutics initiated with a Buy at Chardan
Chardan initiated Seres Therapeutics with a Buy and $15 price target.
GBT Global Blood Therapeutics
$57.45

2.58 (4.70%)

06/14/19
WELS
06/14/19
NO CHANGE
WELS
Outperform
Global Blood Therapeutics data should support 'rapid approval,' says Wells Fargo
Wells Fargo analyst Jim Birchenough reiterates an Outperform rating on Global Blood Therapeutics following release of the final Hope Phase 3 results for hemoglobin modifier voxelotor in sickle cell disease. The analyst expects the data to support "rapid approval and commercial success" in sickle cell. He notes that no patient discontinued due to an adverse event with the exception of a single patient in the placebo group.
06/03/19
WEDB
06/03/19
NO CHANGE
Target $107
WEDB
Outperform
Global Blood Therapeutics price target raised to $107 from $95 at Wedbush
Wedbush analyst Liana Moussatos raised her price target for Global Blood Therapeutics to $107 from $95 given reduced clinical, regulatory, commercial and manufacturing risk along with sufficient cash for initial U.S. launch, strong IP and upside potential from multiple potentially material catalysts and as more investors appreciate that FDA is not solely focused on VOC as a primary endpoint for SCD. The analyst reiterates an Outperform rating on the shares.
05/29/19
GSCO
05/29/19
INITIATION
Target $75
GSCO
Neutral
Global Blood Therapeutics assumed with a Neutral at Goldman Sachs
Goldman Sachs analyst Paul Choi assumed coverage of Global Blood Therapeutics with a Neutral rating and $75 price target. Prior analyst Terence Flynn had a Neutral rating on the shares with a $59 price target. Choi believes the company's lead asset voxelotor could "shift the paradigm" in the treatment of sickle cell disease, but he believes investors should await more more visibility on the clinical and commercial outcomes.
06/14/19
CANT
06/14/19
NO CHANGE
Target $110
CANT
Overweight
Global Blood price target raised to $110 from $96 at Cantor Fitzgerald
Cantor Fitzgerald analyst Elemer Piros raised his price target for Global Blood Therapeutics to $110 from $96 saying the Hope trial indicates "disease-modifying potential" of voxelotor in sickle cell disease. The analyst reiterates an Overweight rating on the shares. Global Blood in premarket trading is down 6%, or $3.22, to $54.30.
WHF WhiteHorse Finance
$14.50

(0.00%)

01/16/19
JPMS
01/16/19
DOWNGRADE
Target $13.5
JPMS
Underweight
WhiteHorse Finance downgraded to Underweight from Neutral at JPMorgan
JPMorgan analyst Richard Shane downgraded WhiteHorse Finance to Underweight with a $13.50 price target.
01/16/19
JPMS
01/16/19
NO CHANGE
JPMS
JPMorgan resets ratings across Specialty Finance sector
The prospect of a prolonged government shutdown and global trade uncertainty threatens what has been "steady, reliable domestic growth," JPMorgan analyst Richard Shane tells investors in a research note on the Specialty Finance sector. Further, the analyst believes the outlook for Fed action has become more clouded. However, Shane thinks sentiment across his sector seems to reflect uncertainty, which gives him an "increasingly positive bias" to the group. He sees the most upside potential among consumer finance names, with late cycle uncertainty "potentially dampening" upside among commercial mortgage real estate investment trusts. Shane this morning upgraded a host of names: Navient (NAVI), OneMain Holdings (OMF) and KKR Real Estate Finance Trust (KREF) to Neutral from Underweight and TCG BDC (CGBD), Annaly Capital (NLY) and Apollo Commercial (ARI) to Overweight from Neutral. Today's downgrades are Santander Consumer (SC), BlackRock Capital Investment (BKCC), WhiteHorse Finance (WHF) to Underweight from Neutral along with PennantPark (PNNT) and Granite Point Mortgage (GPMT) to Neutral from Overweight.

TODAY'S FREE FLY STORIES

ESLT

Elbit Systems

$154.55

0.55 (0.36%)

13:41
06/16/19
06/16
13:41
06/16/19
13:41
Hot Stocks
Elbit Systems awarded $50M contract »

Elbit Systems announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMGN

Amgen

$176.09

-0.74 (-0.42%)

13:40
06/16/19
06/16
13:40
06/16/19
13:40
Hot Stocks
Amgen announces BLINCYTO five-year overall survival data »

Amgen announced the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Sep

SILK

Silk Road Medical

$44.80

-0.95 (-2.08%)

13:35
06/16/19
06/16
13:35
06/16/19
13:35
Hot Stocks
Silk Road Medical announces final results for ROADSTER-2 study »

Silk Road Medical…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Aug

  • 26

    Aug

EDIT

Editas Medicine

$21.72

-0.78 (-3.47%)

13:30
06/16/19
06/16
13:30
06/16/19
13:30
Hot Stocks
Editas presents pre-clinical data in Sickle Cell Disease, Beta-Thalassemia »

Editas Medicine announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SNSS

Sunesis

$0.90

-0.055 (-5.79%)

13:28
06/16/19
06/16
13:28
06/16/19
13:28
Hot Stocks
Sunesis announces preliminary data from Phase 1b/2 trial of Vecabrutinib »

Sunesis Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jun

  • 25

    Jun

APLS

Apellis

$21.22

-0.14 (-0.66%)

13:23
06/16/19
06/16
13:23
06/16/19
13:23
Hot Stocks
Apellis presents data from ongoing Phase 2 PLAUDIT study of APL-2 »

Apellis Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jun

FTSV

Forty Seven

$10.55

-0.02 (-0.19%)

13:16
06/16/19
06/16
13:16
06/16/19
13:16
Hot Stocks
Forty Seven announces data from Phase 1b/2 trial of 5F9 in combo with Rituximab »

Forty Seven announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AZN

AstraZeneca

$39.68

-0.23 (-0.58%)

13:06
06/16/19
06/16
13:06
06/16/19
13:06
Hot Stocks
AstraZeneca announces results from interim analysis of Phase 2 ASCEND trial »

AstraZeneca announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jun

STRO

Sutro Biopharma

$11.17

-0.34 (-2.95%)

13:02
06/16/19
06/16
13:02
06/16/19
13:02
Hot Stocks
Sutro Biopharma announces interim Phase 1 safety data for STRO-001 »

Sutro Biopharma announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BPMC

Blueprint Medicines

$90.65

-0.35 (-0.38%)

12:59
06/16/19
06/16
12:59
06/16/19
12:59
Hot Stocks
Blueprint Medicines presents updated EXPLORER trial data for Avapritinib »

Blueprint Medicines…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jun

INCY

Incyte

$77.76

1.385 (1.81%)

12:52
06/16/19
06/16
12:52
06/16/19
12:52
Hot Stocks
Incyte announced results from Phase 2 study of Ruxolitinib cream in vitiligo »

Incyte announces 24-week…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jun

ABBV

AbbVie

$78.69

-0.27 (-0.34%)

, INCY

Incyte

$77.76

1.385 (1.81%)

04:55
06/16/19
06/16
04:55
06/16/19
04:55
Conference/Events
European Hematology Association to hold a conference »

24th EHA Congress 2019…

ABBV

AbbVie

$78.69

-0.27 (-0.34%)

INCY

Incyte

$77.76

1.385 (1.81%)

ARQL

ArQule

$8.17

1.88 (29.89%)

AMGN

Amgen

$176.09

-0.74 (-0.42%)

ALXN

Alexion

$117.94

0.65 (0.55%)

AGIO

Agios Pharmaceuticals

$47.97

-1.78 (-3.58%)

AZN

AstraZeneca

$39.68

-0.23 (-0.58%)

BLUE

Bluebird Bio

$117.57

-6.33 (-5.11%)

BMY

Bristol-Myers

$47.57

0.25 (0.53%)

CELG

Celgene

$96.49

0.07 (0.07%)

NVS

Novartis

$89.52

-0.07 (-0.08%)

NSTG

NanoString

$25.96

0.45 (1.76%)

KPTI

Karyopharm

$5.71

-0.04 (-0.70%)

JAZZ

Jazz Pharmaceuticals

$130.43

0.28 (0.22%)

GSK

GlaxoSmithKline

$40.12

0.015 (0.04%)

GILD

Gilead

$66.38

-0.62 (-0.93%)

DSNKY

Daiichi Sankyo

$0.00

(0.00%)

PFE

Pfizer

$42.75

0.24 (0.56%)

PTLA

Portola Pharmaceuticals

$25.78

-0.31 (-1.19%)

QGEN

Qiagen

$39.52

-0.07 (-0.18%)

RHHBY

Roche

$0.00

(0.00%)

RIGL

Rigel Pharmaceuticals

$2.06

-0.06 (-2.83%)

SNY

Sanofi

$42.46

-0.225 (-0.53%)

SGEN

Seattle Genetics

$68.67

-0.33 (-0.48%)

STML

Stemline

$14.20

0.12 (0.85%)

VSTM

Verastem

$1.39

0.125 (9.88%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jun

  • 18

    Jun

  • 20

    Jun

  • 20

    Jun

  • 20

    Jun

  • 21

    Jun

  • 23

    Jun

  • 25

    Jun

  • 25

    Jun

  • 26

    Jun

  • 26

    Jun

  • 27

    Jun

  • 27

    Jun

  • 27

    Jun

  • 28

    Jun

  • 28

    Jun

  • 06

    Jul

  • 25

    Jul

  • 06

    Aug

  • 18

    Aug

  • 19

    Aug

  • 26

    Aug

  • 26

    Aug

  • 28

    Aug

  • 29

    Aug

  • 02

    Sep

  • 03

    Sep

  • 16

    Sep

  • 04

    Nov

  • 04

    Dec

  • 25

    Mar

  • 04

    Apr

AMZN

Amazon.com

$1,870.07

-0.23 (-0.01%)

, GRUB

GrubHub

$70.15

-2.76 (-3.79%)

13:28
06/15/19
06/15
13:28
06/15/19
13:28
Periodicals
Amazon exit gives GrubHub stock boost, Barron's says »

Amazon (AMZN) is…

AMZN

Amazon.com

$1,870.07

-0.23 (-0.01%)

GRUB

GrubHub

$70.15

-2.76 (-3.79%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jun

  • 27

    Jun

  • 10

    Jul

ABC

AmerisourceBergen

$85.01

-1.46 (-1.69%)

, CAH

Cardinal Health

$44.16

-1.13 (-2.50%)

13:20
06/15/19
06/15
13:20
06/15/19
13:20
Periodicals
McKesson, Cardinal Health looking like bargains, Barron's says »

Investors have halved the…

ABC

AmerisourceBergen

$85.01

-1.46 (-1.69%)

CAH

Cardinal Health

$44.16

-1.13 (-2.50%)

MCK

McKesson

$133.19

-1.7 (-1.26%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jun

RTN

Raytheon

$177.38

0.195 (0.11%)

, UTX

United Technologies

$125.30

0.45 (0.36%)

13:09
06/15/19
06/15
13:09
06/15/19
13:09
Periodicals
United Technologies, Raytheon stocks looking cheap, Barron's says »

Shares of United…

RTN

Raytheon

$177.38

0.195 (0.11%)

UTX

United Technologies

$125.30

0.45 (0.36%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jun

  • 17

    Jun

  • 17

    Jun

GRUB

GrubHub

$70.15

-2.76 (-3.79%)

, AMZN

Amazon.com

$1,870.07

-0.23 (-0.01%)

13:04
06/15/19
06/15
13:04
06/15/19
13:04
Periodicals
Food fight extending well beyond restaurant delivery, Barron's says »

Amazon (AMZN) is quitting…

GRUB

GrubHub

$70.15

-2.76 (-3.79%)

AMZN

Amazon.com

$1,870.07

-0.23 (-0.01%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jun

  • 27

    Jun

  • 10

    Jul

GOOGL

Alphabet Class A

$1,086.36

-4.65 (-0.43%)

, GOOG

Alphabet

$1,085.56

-3.52 (-0.32%)

12:59
06/15/19
06/15
12:59
06/15/19
12:59
Periodicals
Facebook, JPMorgan chiefs among Best CEOs of 2019, Barron's says »

Separated into three…

GOOGL

Alphabet Class A

$1,086.36

-4.65 (-0.43%)

GOOG

Alphabet

$1,085.56

-3.52 (-0.32%)

FB

Facebook

$181.35

3.88 (2.19%)

MCD

McDonald's

$205.33

0.85 (0.42%)

JPM

JPMorgan

$109.84

0.26 (0.24%)

BAC

Bank of America

$28.03

0.09 (0.32%)

BLK

BlackRock

$446.96

-1.29 (-0.29%)

BX

Blackstone

$44.13

0.17 (0.39%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jun

  • 19

    Jun

  • 09

    Jul

  • 10

    Jul

  • 16

    Jul

  • 17

    Jul

  • 06

    Aug

  • 27

    Oct

AVGO

Broadcom

$265.99

-15.96 (-5.66%)

, AAPL

Apple

$192.84

-1.93 (-0.99%)

07:17
06/15/19
06/15
07:17
06/15/19
07:17
On The Fly
Week in review: How Trump's policies moved stocks »

Catch up on the top…

AVGO

Broadcom

$265.99

-15.96 (-5.66%)

AAPL

Apple

$192.84

-1.93 (-0.99%)

HNHPF

Hon Hai Precision

$0.00

(0.00%)

UTX

United Technologies

$125.30

0.45 (0.36%)

RTN

Raytheon

$177.38

0.195 (0.11%)

CGC

Canopy Growth

$41.15

-0.64 (-1.53%)

TLRY

Tilray

$38.96

-1.78 (-4.37%)

APHA

Aphria

$6.80

-0.15 (-2.16%)

ACB

Aurora Cannabis

$7.56

(0.00%)

CVSI

CV Sciences

$0.00

(0.00%)

CNTTF

CannTrust Holdings

$0.00

(0.00%)

CRON

Cronos Group

$15.43

-0.92 (-5.63%)

CANN

General Cannabis

$0.00

(0.00%)

IGC

India Globalization Capital

$1.28

0.4201 (48.85%)

MLCPF

MediPharm Labs

$0.00

(0.00%)

ZYNE

Zynerba

$13.03

-0.54 (-3.98%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jun

  • 17

    Jun

  • 17

    Jun

  • 18

    Jun

  • 19

    Jun

  • 21

    Jun

  • 25

    Jun

  • 09

    Jul

ABBV

AbbVie

$78.69

-0.27 (-0.34%)

, ABMD

Abiomed

$250.96

-4.58 (-1.79%)

04:55
06/15/19
06/15
04:55
06/15/19
04:55
Conference/Events
International League of Dermatological Societies to hold a conference »

24th World Congress of…

ABBV

AbbVie

$78.69

-0.27 (-0.34%)

ABMD

Abiomed

$250.96

-4.58 (-1.79%)

BMY

Bristol-Myers

$47.57

0.25 (0.53%)

CELG

Celgene

$96.49

0.07 (0.07%)

LLY

Eli Lilly

$111.74

-0.06 (-0.05%)

JNJ

Johnson & Johnson

$140.08

-0.63 (-0.45%)

NVS

Novartis

$89.52

-0.07 (-0.08%)

PFE

Pfizer

$42.75

0.24 (0.56%)

PG

Procter & Gamble

$111.20

0.28 (0.25%)

SNY

Sanofi

$42.46

-0.225 (-0.53%)

UL

Unilever; also tag UN

$62.61

-0.07 (-0.11%)

UN

Unilever; also tag UL

$61.30

-0.13 (-0.21%)

INCY

Incyte

$77.76

1.385 (1.81%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jun

  • 17

    Jun

  • 26

    Jun

  • 27

    Jun

  • 16

    Jul

  • 25

    Jul

  • 30

    Jul

  • 28

    Aug

  • 03

    Sep

  • 16

    Sep

  • 13

    Nov

  • 04

    Dec

  • 25

    Mar

  • 04

    Apr

BMY

Bristol-Myers

$47.57

0.25 (0.53%)

, GSK

GlaxoSmithKline

$40.12

0.015 (0.04%)

04:55
06/15/19
06/15
04:55
06/15/19
04:55
Conference/Events
European Congress of Rheumatology to hold a conference »

EULAR 2019 will be held…

BMY

Bristol-Myers

$47.57

0.25 (0.53%)

GSK

GlaxoSmithKline

$40.12

0.015 (0.04%)

PFE

Pfizer

$42.75

0.24 (0.56%)

LLY

Eli Lilly

$111.74

-0.06 (-0.05%)

ABBV

AbbVie

$78.69

-0.27 (-0.34%)

NVS

Novartis

$89.52

-0.07 (-0.08%)

RHHBY

Roche

$0.00

(0.00%)

BIIB

Biogen

$227.67

-3.57 (-1.54%)

AMGN

Amgen

$176.09

-0.74 (-0.42%)

SNY

Sanofi

$42.46

-0.225 (-0.53%)

CELG

Celgene

$96.49

0.07 (0.07%)

GILD

Gilead

$66.38

-0.62 (-0.93%)

REGN

Regeneron

$305.19

-2.235 (-0.73%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jun

  • 20

    Jun

  • 26

    Jun

  • 27

    Jun

  • 27

    Jun

  • 25

    Jul

  • 30

    Jul

  • 06

    Aug

  • 18

    Aug

  • 19

    Aug

  • 26

    Aug

  • 26

    Aug

  • 28

    Aug

  • 29

    Aug

  • 02

    Sep

  • 03

    Sep

  • 16

    Sep

  • 04

    Nov

  • 04

    Dec

  • 25

    Mar

  • 04

    Apr

ABBV

AbbVie

$78.69

-0.27 (-0.34%)

, INCY

Incyte

$77.76

1.385 (1.81%)

04:55
06/15/19
06/15
04:55
06/15/19
04:55
Conference/Events
European Hematology Association to hold a conference »

24th EHA Congress 2019…

ABBV

AbbVie

$78.69

-0.27 (-0.34%)

INCY

Incyte

$77.76

1.385 (1.81%)

ARQL

ArQule

$8.17

1.88 (29.89%)

AMGN

Amgen

$176.09

-0.74 (-0.42%)

ALXN

Alexion

$117.94

0.65 (0.55%)

AGIO

Agios Pharmaceuticals

$47.97

-1.78 (-3.58%)

AZN

AstraZeneca

$39.68

-0.23 (-0.58%)

BLUE

Bluebird Bio

$117.57

-6.33 (-5.11%)

BMY

Bristol-Myers

$47.57

0.25 (0.53%)

CELG

Celgene

$96.49

0.07 (0.07%)

NVS

Novartis

$89.52

-0.07 (-0.08%)

NSTG

NanoString

$25.96

0.45 (1.76%)

KPTI

Karyopharm

$5.71

-0.04 (-0.70%)

JAZZ

Jazz Pharmaceuticals

$130.43

0.28 (0.22%)

GSK

GlaxoSmithKline

$40.12

0.015 (0.04%)

GILD

Gilead

$66.38

-0.62 (-0.93%)

DSNKY

Daiichi Sankyo

$0.00

(0.00%)

PFE

Pfizer

$42.75

0.24 (0.56%)

PTLA

Portola Pharmaceuticals

$25.78

-0.31 (-1.19%)

QGEN

Qiagen

$39.52

-0.07 (-0.18%)

RHHBY

Roche

$0.00

(0.00%)

RIGL

Rigel Pharmaceuticals

$2.06

-0.06 (-2.83%)

SNY

Sanofi

$42.46

-0.225 (-0.53%)

SGEN

Seattle Genetics

$68.67

-0.33 (-0.48%)

STML

Stemline

$14.20

0.12 (0.85%)

VSTM

Verastem

$1.39

0.125 (9.88%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Jun

  • 17

    Jun

  • 18

    Jun

  • 20

    Jun

  • 20

    Jun

  • 20

    Jun

  • 21

    Jun

  • 23

    Jun

  • 25

    Jun

  • 25

    Jun

  • 26

    Jun

  • 26

    Jun

  • 27

    Jun

  • 27

    Jun

  • 27

    Jun

  • 28

    Jun

  • 28

    Jun

  • 06

    Jul

  • 25

    Jul

  • 06

    Aug

  • 18

    Aug

  • 19

    Aug

  • 26

    Aug

  • 26

    Aug

  • 28

    Aug

  • 29

    Aug

  • 02

    Sep

  • 03

    Sep

  • 16

    Sep

  • 04

    Nov

  • 04

    Dec

  • 25

    Mar

  • 04

    Apr

ABT

Abbott

$82.25

-0.03 (-0.04%)

, AMGN

Amgen

$176.09

-0.74 (-0.42%)

04:55
06/15/19
06/15
04:55
06/15/19
04:55
Conference/Events
Society for Vascular Surgery to hold annual meeting »

SVS Annual Meeting 2019…

ABT

Abbott

$82.25

-0.03 (-0.04%)

AMGN

Amgen

$176.09

-0.74 (-0.42%)

BSX

Boston Scientific

$40.41

-0.26 (-0.64%)

PFE

Pfizer

$42.75

0.24 (0.56%)

CRY

CryoLife

$29.13

-0.13 (-0.44%)

EW

Edwards Lifesciences

$184.00

-0.63 (-0.34%)

ELGX

Endologix

$7.61

0.2 (2.70%)

IAC

IAC

$228.41

-2.63 (-1.14%)

HCA

HCA Healthcare

$126.64

-0.76 (-0.60%)

LMAT

LeMaitre

$26.04

-0.44 (-1.66%)

ORGO

Organogenesis

$7.39

0.02 (0.27%)

OSIR

Osiris

$0.00

(0.00%)

PEN

Penumbra

$166.75

2.93 (1.79%)

SWAV

ShockWave Medical

$58.27

-0.99 (-1.67%)

WTKWY

Wolters Kluwer

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jun

  • 26

    Jun

  • 09

    Aug

  • 26

    Aug

  • 26

    Aug

  • 28

    Aug

  • 16

    Sep

  • 25

    Sep

  • 13

    Nov

CNC

Centene

$53.52

-0.26 (-0.48%)

, WCG

WellCare

$287.16

0.145 (0.05%)

18:45
06/14/19
06/14
18:45
06/14/19
18:45
Hot Stocks
Centene CEO: Medicare for all will not work »

In an interview on…

CNC

Centene

$53.52

-0.26 (-0.48%)

WCG

WellCare

$287.16

0.145 (0.05%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Jun

  • 24

    Jun

  • 24

    Jun

  • 23

    Jul

HMC

Honda

$25.34

-0.405 (-1.57%)

18:24
06/14/19
06/14
18:24
06/14/19
18:24
Hot Stocks
Honda recalls all 2016-2019 model year Pioneer vehicles »

Honda is conducting a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RH

RH

$111.28

1.42 (1.29%)

18:22
06/14/19
06/14
18:22
06/14/19
18:22
Hot Stocks
RH CEO: We think our stock is massively undervalued »

In an interview on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.